These findings, together with previously published data (45, 46) and our pan-cancer genomic analyses of LIG1 aberrations, provide evidence for the use of PARPi as a treatment approach for a spectrum of tumors (e.g., PCa, LUAD, BRCA, COAD, and potentially OV) characterized by LIG1 defects. This evidence concerns the gene LIG1 and cancer.